Christopher Birk

Christopher Birk obtained his MSc in Biochemistry at the Julius-Maximilians-Universität Würzburg in 2024. During his master’s thesis, he worked on the delivery of antisense oligonucleotide-based therapeutics into the gram-positive, obligate anaerobe pathogen Clostridioides difficile. After a research stay in Uppsala (Sweden), Christopher returned to the Faber group in 2024 to pursue his PhD. His project aims to establish bacterial single-cell RNA-seq in Clostridioides difficile to characterize the molecular principles that give rise to the highly heterogenous production of toxins and endospores—essential virulence traits responsible for intestinal inflammation and host transmission.